The phenotype of hematopoietic cells transformed by the BCR͞ABL oncoprotein of the Philadelphia chromosome is characterized by growth factor-independent proliferation, reduced susceptibility to apoptosis, and altered adhesion and motility. The mechanisms underlying this phenotype are not fully understood, but there is evidence that some of the properties of BCR͞ABL-expressing cells are dependent on the activation of downstream effector molecules such as RAS, PI-3k, and bcl-2. We show here that the small GTP-binding protein Rac is activated by BCR͞ABL in a tyrosine kinase-dependent manner. Upon transfection with a vector carrying the dominant-negative N17Rac, BCR͞ABL-expressing myeloid precursor 32Dcl3 cells retained the resistance to growth factor deprivation-induced apoptosis but showed a decrease in proliferative potential in the absence of interleukin-3 (IL-3) and markedly reduced invasive properties. Moreover, compared with BCR͞ABL-expressing cells, fewer BCR͞ABL plus N17Rac double transfectants were capable of homing to bone marrow and spleen. Consistent with these findings, survival of SCID mice injected with the BCR͞ABL plus N17Rac double transfectants was markedly prolonged as compared with that of mice injected with BCR͞ ABL-expressing cells. Together, these data support the important role of a Rac-dependent pathway(s) controlling motility in BCR͞ABL-mediated leukemogenesis.
Bcr͞abl is a chimeric oncogene generated from a chromosomal translocation between chromosomes 9 and 22 (Philadelphia chromosome), which juxtaposes sequences from the bcr gene with sequences upstream of the second exon of c-abl. Bcr͞abl genes encode two proteins: p185, which contains a smaller BCR portion (amino acids 1 to 426) and is associated with acute lymphocytic leukemia (1); and p210, which contains a larger BCR portion (amino acids 1-902 or 926) and is found in most cases of chronic myelogenous leukemia (2) . Both BCR͞ABL chimeric proteins are constitutively active tyrosine kinases that can transform fibroblasts and hematopoietic cells in culture (3) (4) (5) and induce leukemia in mice (6, 7) . BCR͞ ABL-dependent transformation of hematopoietic cells is associated with the activation of several downstream effector molecules (8) , some of which appear to be essential for leukemogenesis both in vitro and in vivo. For example, BCR͞ ABL-dependent leukemogenesis is suppressed when antisense strategies, expression of proteins with dominant-negative activity, or specific chemical inhibitors are used to inhibit the function of RAS, RAF, PI-3k, Akt, and bcl-2 (9-13). Suppression of the activity of these BCR͞ABL-regulated molecules is associated with inhibition of proliferation and enhanced susceptibility to apoptosis. In addition to growth factor-independent proliferation and reduced susceptibility to apoptosis, the phenotype of BCR͞ABL-expressing cells is characterized also by altered trafficking, which may reflect defects in cell-cell communication and cell-extracellular matrix interactions (14, 15) . Specific downstream effectors might regulate the trafficking of BCR͞ABL-expressing cells.
In this study, we show that the activity of Rac, a small G protein recently shown to function as a regulator of the integrin-dependent motility and invasiveness of epithelial tumor cells (16, 17) , is enhanced in 32Dcl3 growth factordependent myeloid precursor cells ectopically expressing wildtype BCR͞ABL. Upon transfection with a dominant-negative Rac, these cells exhibit a marked suppression of invasive properties, while proliferation was only marginally affected and there were no changes in apoptosis susceptibility. In vivo, the leukemogenic potential of 32Dcl3 cells coexpressing wildtype BCR͞ABL and dominant-negative Rac was markedly impaired and correlated with a reduced ability of these cells to home to bone marrow and spleen of mice.
Together, these studies support the essential role of RAC as a regulator of BCR͞ABL-dependent leukemogenesis by mechanisms that promote enhanced motility and invasiveness.
MATERIALS AND METHODS
Retroviral Constructs. The p210 BCR͞ABL bcr exon 3͞abl exon 2 cDNA was cloned into the EcoRI-HindIII sites of the pSRaMSVtkneo retroviral vector (12) . In this vector, the BCR͞ABL cDNA is under the control of the long terminal repeat of the murine sarcoma virus (MSV), whereas the neomycin resistance gene is driven by the herpes simplex thymidine kinase (tk) promoter.
The N17Rac and V12Rac cDNAs were obtained from C. J. Der (University of North Carolina, Chapel Hill, NC) and L. Van Aelst (Cold Spring Harbor Laboratory), respectively. Both mutants were cloned into the BamHI site of the LXSP retroviral vector. In the LXSP vector, the Rac cDNA is under the control of the long terminal repeat of the Moloney murine leukemia virus, whereas the puromycin resistance gene is driven by the simian virus 40 (SV40) early promoter.
32Dcl3 Cell Transfection. N17Rac was electroporated into p210BCR͞ABL-32Dcl3 murine myeloid precursor cells (12) grown in Iscove's modified Dulbecco medium (IMDM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, penicillin͞streptomycin (100 g͞ml each), and 15% WEHIconditioned medium (WEHI-CM) as a source of IL-3. N17Rac-expressing clones were selected in puromycin (2 g͞ ml) and were maintained in IMDM-CM.
Northern Blot Analysis. Total cellular RNA (10 g͞lane) was electrophoresed on agarose gels and blotted onto a
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nitrocellulose PROTRAN membrane (Schleicher & Schuell). Full-length N17Rac cDNA labeled with [␣-32 P]dCTP (NEN) was used as probe.
Infection of Bone Marrow Cells. Helper-free retroviral stocks were prepared as described (18, 19) . Bone marrow cells from C57BL͞6TacfBR mice (The Jackson Laboratory) treated with 5-fluorouracil (150 mg͞kg body weight) 6 days before cell harvest were infected with BCR͞ABL and͞or Rac retroviruses or the insert-less retrovirus as described (19) . BCR͞ABL and Rac transcripts were detected by reverse transcriptase-PCR by using total RNA isolated from 10 5 -infected cells. The BCR͞ ABL transcript (332 bp) was amplified by using the 5Ј (BCR) primer: CACAGCATTCCGCTGACCATCA and the 3Ј (ABL) primer: GCTTCACACCATTCCCCATTGT, which span the BCR͞ABL junction. The LXSP-Rac transcript (199 bp) was amplified with the 5Ј (LXSP) primer: CGATCCTC-CCTTTATCCAGCC and the 3Ј (Rac) primer: TCTAC-CATAACATTGG-CAGA. The ␤-actin transcript (210 bp) also was detected in each sample as control for RNA loading and integrity (11) .
Rac-1 GDP͞GTP Exchange. The coding region of the murine Rac-1 gene was amplified by reverse transcriptase-PCR from 32Dcl3 RNA and cloned in-frame at the EcoRI and XhoI sites of pGTX-4T-1 (Pharmacia). After transformation of Escherichia coli BL21 cells, purified GST-Rac-1 protein was bound to [ 3 H]GDP (1.05 Ci) in 180 l of binding buffer (20 m Tris, pH 7.5͞1 mM Mg Cl 2 ͞1 mM DTT͞100 mM NaCl,͞40 g/ml BSA) for 1 h at 32°C. Cell extracts of 5 ϫ 10 7 parental or BCR͞ABL-expressing 32Dcl3 cells starved for 5 h in IMDM supplemented with 0.1% BSA, and 2 mM L-glutamine was immunoprecipitated with antibody against Vav, a protooncogene shown to act as a guanine exchange factor for Rac (20) , which is constitutively active in BCR͞ABL-expressing cells (21) . Anti-Vav immunoprecipitates were incubated with Clonogenic Assay. Bone marrow cells (10 5 ) were plated in MethoCult H4230 semisolid methyl-cellulose medium (Stem Cell Technologies, Vancouver, CA) in the presence or absence of threshold concentrations of recombinant murine IL-3 (rmuIL-3; Genetics Institute, Cambridge, MA) as described (9) . Colonies were scored on day 12.
Proliferation Assay. Cells (10 4 ͞0.1 ml) were plated in a 96-well plate with or without WEHI-CM. The number of living cells was scored daily by Trypan blue exclusion test.
Apoptosis Assay. Cells (2 ϫ 10 5 ͞ml) were incubated in IMDM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and penicillin͞streptomycin (100 g͞ml each) for 24, 48, and 72 h. The percentage of apoptotic cells was determined by using the TACS1 Klenow in situ apoptosis detection kit (Trevigen, Gaithersburg, MD) according to the manufacturer's protocol.
Invasion Assay. For the invasion assay, 32Dcl3 cells (10 6 ) expressing wild-type BCR͞ABL or coexpressing BCR͞ABL and N17Rac were suspended in 2 ml of IMDM and placed in the upper chamber of a Biocoat Matrigel invasion chamber (Becton Dickinson); the lower chamber was filled with 2 ml of IMDM-CM as chemoattractant. Cells migrating into the lower chamber were counted 24 h later. Cells remaining on the membrane were counted after washing and staining the membrane according to the manufacturer's protocol.
Homing Assay. Cells were labeled with [ 3 H]uridine (NEN), (0.5 Ci͞ml IMDM-CM medium) for 24 h at 37°C, washed, and injected i.v. into SCID mice (5 ϫ 10 6 cells͞mouse) (22) . Bone marrow (from both femurs) and spleen cells were collected 24 h later and deposited onto glass microfiber filters (Whatman). Cell-associated radioactivity was measured in a ␤-scintillation counter.
Leukemogenesis in SCID Mice. C.B-17͞IcrTac-SCID male mice (Taconic Farms) were injected i.v. with 5 ϫ 10 6 32Dcl3 cells expressing BCR͞ABL or BCR͞ABL plus N17Rac proteins. Mice were killed 3 weeks after cell injection, and leukemia development was monitored by histopathological analysis.
RESULTS

Activation of Rac in BCR͞ABL-Expressing 32Dcl3 Myeloid
Precursor Cells. The Vav protooncogene has been recently shown to function as a guanine exchange factor for Rac (21) . Moreover, Vav is activated by tyrosine phosphorylation in growth factor-stimulated hematopoietic cells and in cells expressing the BCR͞ABL oncoprotein (22 Requirement for Rac Activity in Proliferation but Not Survival of Growth Factor-Deprived BCR͞ABL-Expressing Cells. Two different clones of 32Dcl3 cells expressing wild-type BCR͞ABL were electroporated with an insert-less vector or with a plasmid carrying a mutant cDNA encoding the N17Rac protein, which exhibits dominant-negative activity. After selection in puromycin (2 g͞ml), clones were screened for Rac expression, and three of them with similar levels of Rac transcripts (data not shown) were analyzed for growth factorindependent proliferation and apoptosis susceptibility.
In the absence of IL-3-containing WEHI-CM, BCR͞ABL-expressing 32Dcl3 cells proliferated faster than cells coexpressing wild-type BCR͞ABL and N17Rac (Fig. 2 Upper) (Fig. 2 Upper) . The 32Dcl3 cells expressing wild-type BCR͞ABL only or coexpressing the dominant-negative RAC were completely resistant to apoptosis induced by growth factor deprivation (Fig. 3) . Further analysis of the requirement for Rac in proliferation of BCR͞ABL-expressing cells by using primary mouse bone marrow cells infected with a retrovirus carrying the wild-type BCR͞ABL or with both wild-type BCR͞ABL and the dominant-negative N17Rac, showed that expression of the dominant-negative N17Rac reduced colony formation in both IL-3-deprived and IL-3-supplemented (0.1 unit͞ml) cultures (Fig.  4) . Colony formation was enhanced by coexpression of BCR͞ ABL and the constitutively active V12Rac, whereas expression of V12Rac alone had no effect (Fig. 4) .
Effect of Dominant-Negative N17Rac Expression on Invasion and Homing of BCR͞ABL-Expressing 32Dcl3 Cells. To assess the requirement for a functional Rac in the invasion of BCR͞ABL-expressing cells, assays of invasion of artificial membranes were performed with 32Dcl3 cells expressing BCR͞ABL only or coexpressing N17Rac. In the invasion assays, the number of BCR͞ABL-expressing 32Dcl3 cells capable of passing through the artificial membrane was Ϸ3-fold less than that of 32Dcl3 cells coexpressing BCR͞ABL and dominant-negative N17Rac (Fig. 5) , whereas a high proportion of BCR͞ABL and N17Rac expressing cells remained attached to the membrane (Fig. 5) .
To determine whether the N17Rac-dependent effects on the invasion of BCR͞ABL-expressing 32Dcl3 cells might be reflected in a reduced in vivo homing to hematopoietic tissues, 32Dcl3 transfectants were labeled with [ into SCID mice, and evaluated 24 h later for percent radioactivity in bone marrow and spleen. Expression of dominantnegative N17Rac reduced the homing ability of BCR͞ABL-transfected 32Dcl3 cells, as indicated by a 50-75% decrease in bone marrow-and spleen-associated radioactivity (Fig. 6) .
Requirement of Rac Activity for BCR͞ABL-Mediated Leukemogenesis in Vivo. To determine whether Rac plays an essential role in BCR͞ABL-mediated leukemogenesis in vivo, SCID mice were injected with 32Dcl3 cells expressing wildtype BCR͞ABL only or coexpressing dominant-negative N17Rac, and 3 weeks later, various organs obtained from three mice of each injected group were evaluated by visual inspection and light microscopy. All three mice injected with wildtype BCR͞ABL-expressing cells showed massive splenomegaly. Hematoxylin͞eosin-stained sections demonstrated that the normal architecture of the spleen was extensively replaced by blasts with a low degree of myeloid maturation. Bone marrows were characterized by extensive chronic myelogenous leukemia-like myeloproliferation or overt acute myelogenous leukemia, although these cells usually demonstrated a higher degree of myeloid maturation than those in other organs. Acute myelogenous leukemia also involved livers in an intrasinusoidal infiltrate pattern, with occasional small parenchymal foci, and kidneys and lungs in two of three mice. By contrast, spleens of mice injected with 32Dcl3 cells coexpressing wild-type BCR͞ABL and dominant-negative N17Rac were minimally enlarged; histopathologic analysis of various organs revealed normal architecture and no evidence of leukemic infiltrates in bone marrow, liver, kidneys, or lungs. Mild myelo-erythroid hyperplasia was detected in spleen (not shown). Consistent with these findings, the survival of mice injected with 32Dcl3 cells coexpressing wild-type BCR͞ABL and dominant-negative N17Rac was Ϸ4-fold longer than that of mice injected with cells expressing wild-type BCR͞ABL only (Fig. 7) , although necropsy revealed splenomegaly and diffuse leukemia in various organs of mice injected with cells coexpressing wild-type BCR͞ABL and dominant-negative N17Rac (not shown). Thus, Rac is required for the leukemogenic potential of wild-type BCR͞ABL, but the disease process induced by wild-type BCR͞ABL-expressing cells was not completely suppressed by inhibition of Rac activity.
DISCUSSION
The phenotype of BCR͞ABL-expressing cells is characterized by growth factor-independent proliferation (8, 23) , reduced susceptibility to apoptosis induced by growth factor deprivation and by other stimuli (8, 24) , and abnormal adhesion͞ invasion to artificial and physiological substrates that correlates with altered in vivo trafficking (14, 15, 22) . The mechanisms whereby BCR͞ABL induces this phenotype are only partially understood; moreover, it is unknown whether the various properties of BCR͞ABL-expressing cells are under the control of distinct BCR͞ABL-dependent pathways. For example, a functional RAS is required for both proliferation and survival of BCR͞ABL-expressing cells (9, 25) , and the BCR͞ ABL-dependent activation of the PI-3k͞Akt pathway appears to transduce both survival and proliferative signals (12) . In contrast, a BCR͞ABL mutant lacking the SH3 domain renders transfected cells growth factor-independent and resistant to apoptosis but is defective in enhancing the invasive potential of transfected cells and in promoting their optimal homing to bone marrow and spleen. The aim of the present study was to identify a BCR͞ABL downstream effector(s) involved in regulation of motility and to determine whether the regulation of this process was independent of the effects on proliferation and survival. An in vivo model of leukemia also was used to test whether interfering with a pathway regulating cell motility might adversely affect the leukemogenic potential of BCR͞ ABL.
The small GTP-binding protein Rac is critically important for the motility and the invasive phenotype of fibroblasts and epithelial cells (16, 17) , raising the possibility that it also might be required for the trafficking of BCR͞ABL-expressing cells. Indirect evidence for BCR͞ABL-dependent Rac activation was obtained in experiments demonstrating that anti-Vav immunoprecipitates from BCR͞ABL-expressing cells function as a guanine exchange factor for Rac (Fig. 1) . As expected, Vav was tyrosine phosphorylated in BCR͞ABL-expressing 32Dcl3 cells, but not in IL-3-starved parental cells or in cells transfected with a tyrosine kinase-deficient BCR͞ABL mutant (not shown). The mechanism(s) of BCR͞ABL-dependent Rac activation is unknown presently except for the requirement of a functional tyrosine kinase (not shown). In other models, Rac activation has been placed downstream of RAS, but it is not yet clear whether Rac is directly activated by RAS or requires PI-3k as a functional bridge between RAS and Rac (26, 27) . The role of PI-3k in Rac activation also is unclear because it has been placed, functionally, both upstream and downstream of Rac (17, 18) .
Because RAS and PI-3k are regulated independently by BCR͞ABL and require for their activation the interaction of adapter molecules with more than one domain of the BCR͞ ABL oncoprotein (12, 28) , it seems likely that the mechanisms of Rac activation are also complex. Assays of Rac activity in In vitro, the functional consequences of inhibiting Rac activity in BCR͞ABL-expressing cells were manifested in a reduced proliferative potential in growth factor-deprived cultures and in altered invasive properties. This phenotype was not surprising based on previous reports suggesting a role for Rac in cell cycle progression (29, 30) and in integrin-dependent cell adhesion and motility (16, 17) . Interestingly, inhibition of Rac activity had no adverse effects on the survival of BCR͞ ABL-expressing cells, indicating that the regulation of cell growth by Rac is independent of effects on survival. This contrasts with the requirement for RAS in both proliferation and survival of BCR͞ABL-expressing cells (9, 22) . It seems unlikely that the altered invasive properties of 32Dcl3 cells expressing BCR͞ABL and N17Rac are the consequence of the reduced proliferative potential of the doubly transfected cells; the reduced proliferation of these cells in growth factordeprived cultures was modest, compared with the effects observed in the assays monitoring the invasive properties. The effects in invasion induced by dominant-negative Rac expression in BCR͞ABL-expressing cells were not associated with changes in the levels of ␣1, ␣2, or ␤1 integrins (not shown), suggesting that Rac either functions as a mediator of integringenerated signals (17) or induces changes in integrin's affinity rather than in expression that might be responsible for the altered invasive properties of the double transfectants. Compared with wild-type BCR͞ABL-expressing cells, BCR͞ABL plus N17Rac transfectants showed markedly impaired leukemogenic potential. This might be the consequence, in part, of the reduced proliferation of the N17Rac-expressing cells; however, the defect in invasion that correlates with reduced homing to bone narrow and spleen is more likely to be the primary determinant of the lower leukemogenicity of the double-transfected cells. In SCID mice, levels of IL-3 and of other growth-promoting cytokines might be sufficient for optimal proliferation of BCR͞ABL plus N17Rac-doubletransfected cells, and yet the homing and the leukemogenic potential of these double transfectants were markedly suppressed. Thus, it is likely that separate Rac-dependent pathways exist for proliferation and motility. The lower leukemogenic potential of the double transfectants might depend not only on a reduced cell accumulation in hematopoietic and nonhematopoietic tissues as a consequence of altered adhesion and motility, but also on an impairment in the response to microenvironment-regulated signals that promote proliferation and survival (31) .
In summary, we have identified Rac as a BCR͞ABL downstream effector with an important role in leukemogenesis. The distinct involvement of Rac in pathways regulating cell trafficking as compared with cell survival points to the possibility of developing therapeutic strategies that combine compounds able to disrupt cell motility and promote apoptosis.
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